Search Results for "meetings"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for meetings. Results 161 to 170 of 172 total matches.
Cefiderocol (Fetroja) - A New IV Cephalosporin for Complicated UTI
The Medical Letter on Drugs and Therapeutics • May 04, 2020 (Issue 1597)
. Meeting of the
Antimicrobial Drugs Advisory Committee (AMDAC). October 16,
2019. Available at: https ...
The FDA has approved cefiderocol (Fetroja – Shionogi),
a new IV cephalosporin antibiotic, for treatment of
complicated urinary tract infections (UTI) caused by
susceptible gram-negative bacteria in adults who
have limited or no alternative treatment options.
Treatment of Clostridium difficile-Associated Disease (CDAD)
The Medical Letter on Drugs and Therapeutics • Nov 06, 2006 (Issue 1247)
diarrhea (CDAD). 44th Annual Meeting of IDSA in Toronto,
Canada, October 12-15, 2006; page 60, abstract ...
The gram-positive anaerobic bacillus Clostridium difficile is the most common identifiable cause of antibiotic-associated diarrhea. The antibiotics most often implicated have been ampicillin, second and third generation cephalosporins, clindamycin and fluoroquinolones. The emergence in recent years of a new, more toxic epidemic strain (BI/NAP1), possibly related to widespread use of fluoroquinolones, has caused a marked increase in the incidence and severity of C. difficile-associated disease (CDAD).
Erythropoietin Safety Concerns
The Medical Letter on Drugs and Therapeutics • May 07, 2007 (Issue 1260)
or
radiotherapy. Presented at the 2007 annual meeting of the
American Association for Cancer Research, April 14 ...
The erythropoiesis-stimulating agents (ESAs) epoetin alfa (Epogen, Procrit) and darbepoetin alfa (Aranesp) are widely used for treatment of anemia and to reduce the need for red blood cell transfusions. Based on the results of recent clinical trials indicating an increased risk of serious adverse events and death associated with ESAs, particularly when used to achieve a hemoglobin concentration ≥12 g/dL, the FDA has revised the prescribing information for these drugs to include a black box warning.
Who Should Take Vitamin Supplements?
The Medical Letter on Drugs and Therapeutics • Dec 12, 2011 (Issue 1379)
daily dietary intake
level that is sufficient to meet the nutrient requirements of most healthy
adults ...
Many patients ask their healthcare providers whether
they should take vitamins. Since the last Medical Letter
article on this subject, more data have become available
on the benefits and risks of taking vitamins.
Drugs for Open-Angle Glaucoma
The Medical Letter on Drugs and Therapeutics • Apr 28, 2025 (Issue 1727)
as timolol 0.5% solution in patients
with a baseline IOP of ...
Glaucoma is a progressive optic neuropathy
associated with increased intraocular pressure
(IOP; normal range 8-22 mm Hg), which is the only
disease-related factor that can be modified. Topical
drugs that lower IOP are the first line of treatment for
open-angle glaucoma.
Med Lett Drugs Ther. 2025 Apr 28;67(1727):65-8 doi:10.58347/tml.2025.1727a | Show Introduction Hide Introduction
Vaccines for Travelers
The Medical Letter on Drugs and Therapeutics • Nov 19, 2018 (Issue 1560)
. Available at: www.cdc.gov/vaccines/
acip/meetings/downloads/min-archive/min-2018-02-508.pdf.
Accessed ...
Persons planning to travel outside the US should be
up to date on routine vaccines and, depending on their
destination, duration of travel, and planned activities,
may also receive certain travel-specific vaccines.
Tickborne encephalitis and dengue vaccines, which
are not available in the US, are reviewed in a separate
article available online. Detailed advice for travel to
specific destinations is available from the Centers for
Disease Control and Prevention (CDC) at www.cdc.gov/travel/destinations/list. Recommendations for
administration of vaccines as part of routine...
Drugs for Alcohol Use Disorder
The Medical Letter on Drugs and Therapeutics • Dec 13, 2021 (Issue 1639)
(AUD; previously called alcohol
dependence) as meeting ≥2 of the 11 criteria listed in
Table 1 ...
Consumption of alcohol has increased during the
COVID-19 pandemic. The Diagnostic and Statistical
Manual for Mental Disorders, 5th edition (DSM-5) defines
alcohol use disorder (AUD; previously called alcohol
dependence) as meeting ≥2 of the 11 criteria listed in
Table 1 in the past year. The lifetime prevalence of AUD
in the US population has been estimated to be about
30%. Despite this high prevalence and the associated
morbidity, mortality, and costs, only 3 drugs are FDA-approved
for treatment of the disorder.
Drugs and Devices for Weight Management
The Medical Letter on Drugs and Therapeutics • Aug 04, 2025 (Issue 1734)
4 RCT. 42nd
Annual Meeting of The Obesity Society at ObesityWeek; San
Antonio, TX; November 3–6 ...
Overweight is generally defined as a body mass
index (BMI) between 25 and 29.9 kg/m2 in adults. A
BMI ≥30 is considered obese (criteria differ slightly in
Asian patients). In patients with an elevated BMI, a
5-10% reduction in weight has been associated with
a reduction in the risk of developing type 2 diabetes,
hypertension, and dyslipidemia. Diet, exercise, and
behavior modification are the traditional methods
for losing weight, but they are often inadequate; the
American College of Cardiology no longer recommends
that all patients try lifestyle modification alone before
adding...
Med Lett Drugs Ther. 2025 Aug 4;67(1734):121-8 doi:10.58347/tml.2025.1734a | Show Introduction Hide Introduction
Drugs for Common Eye Disorders
The Medical Letter on Drugs and Therapeutics • Dec 02, 2019 (Issue 1586)
in patients with a baseline IOP of ...
This issue includes reviews of drugs for glaucoma,
age-related macular degeneration (AMD), bacterial
conjunctivitis, and dry eye disease. Allergic conjunctivitis
is reviewed in a separate issue.
Treatment of Allergic Rhinitis and Allergic Conjunctivitis
The Medical Letter on Drugs and Therapeutics • Mar 31, 2025 (Issue 1725)
of oral phenylephrine as
a nasal decongestant. Nonprescription Drugs Advisory
Committee meeting ...
Initial treatment of allergic rhinitis (AR) depends
on the severity of symptoms and whether they are
intermittent or persistent (see Table 1).
Med Lett Drugs Ther. 2025 Mar 31;67(1725):49-56 doi:10.58347/tml.2025.1725a | Show Introduction Hide Introduction